Concepedia

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

Melanie J. Davies, Peter van der Meer, Subodh Verma, Shachi Patel, Khaja Chinnakondepalli, Barry A Borlaug, Javed Butler, Dalane W Kitzman, Sanjiv J Shah, Signe Harring,

The Lancet Diabetes & Endocrinology · 2025 · 19 citations · 16 references

DOIFull text

Open access

Concepts

References

16

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark et al. · New England Journal of Medicine · 2019 · 1.9K citations · Full text

, , +16

Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure

C.Patrick Green, Charles Porter, Dennis R. Bresnahan et al. · Journal of the American College of Cardiology · 2000 · 1.8K citations

, , +8

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

Mikhail Kosiborod, Steen Z. Abildstrøm, Barry A. Borlaug et al. · New England Journal of Medicine · 2023 · 1.4K citations · Full text

, , +17

The Hazards of Hazard Ratios

Miguel A. Hernán · Epidemiology · 2009 · 1.3K citations

, , +15

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Melanie J. Davies, Louise Færch, Ole Kleist Jeppesen et al. · The Lancet · 2021 · 1.3K citations · Full text

, , +10